Rubicon subsidiary to invest up to USD 3 million in Gen1E Lifesciences

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

RUBICON · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.5%Reaction day

₹612.50

prior close

₹612.30

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.5%-2.1% vs market

Pharmaceuticals peers, median of 156sector-0.7%-1.9% vs sector

On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250 and 1.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

-0.9

15m

-1.0

30m

-1.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.5-0.5-2.1-0.7-1.9

Next day

-6.3-0.8-5.5-0.9-5.4

-3.3-0.4-2.9-0.9-2.5

+1.6-0.2+1.7-0.9+2.4

-2.0+0.3-2.3-0.4-1.6

-0.8+0.1-0.9-0.0-0.8

+8.1+0.8+7.3+0.1+8.0

15d

+16.2-1.2+17.3-1.6+17.8

+7.3-3.9+11.3-4.1+11.4

+12.5-5.0+17.5-5.0+17.5

+5.7-13.9+19.6-12.4+18.1

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Rubicon's wholly owned subsidiary Advagen Holdings signed a definitive agreement to buy Gen1E Lifesciences preferred shares. The deal provides USD 2 million cash in two tranches by March 2026 and up to USD 1 million through milestone-linked share issuance until December 2027. If all milestones are met, the investment would represent about 2.2% of Gen1E common stock. Gen1E develops pharmaceutical products, is based in California and has no revenue.

Likely market impact

Rubicon gains a small foothold in drug development, but Gen1E has no revenue and returns are uncertain. Rubicon's exposure can reach USD 3 million.